📊 ETON Key Takeaways
Is Eton Pharmaceuticals, Inc. (ETON) a Good Investment?
Eton Pharmaceuticals demonstrates strong revenue growth of 104.9% YoY and positive free cash flow of $10.2M, indicating improving operational scale and cash generation. However, the company remains unprofitable with negative net income of -$4.6M and operating losses, while carrying significant debt of $21.8M that exceeds available cash reserves, presenting execution and solvency risks.
Eton Pharmaceuticals is showing strong fundamental momentum, with revenue more than doubling year over year and free cash flow turning meaningfully positive, which suggests its growth is translating into real cash generation. The main constraint is that profitability is still not fully established, with negative net income, thin operating margin, and weak interest coverage, but the business appears close to operating breakeven with a manageable liquidity position.
Why Buy Eton Pharmaceuticals, Inc. Stock? ETON Key Strengths
- Revenue growth of 104.9% YoY demonstrates strong top-line expansion
- Healthy gross margin of 53.5% indicates pricing power and favorable product mix
- Positive free cash flow of $10.2M (12.7% FCF margin) shows cash generation capability
- Current ratio of 1.57x and quick ratio of 1.17x indicate adequate short-term liquidity
- Revenue growth of 104.9% YoY indicates strong commercial execution and expanding product contribution
- Positive operating cash flow of $10.52M and free cash flow of $10.19M show improving earnings quality and cash conversion
- Gross margin of 53.5% and cash balance of $25.94M provide a reasonable foundation for continued scaling
ETON Stock Risks: Eton Pharmaceuticals, Inc. Investment Risks
- Company is unprofitable with net loss of -$4.6M and operating margin of -1.1%
- Negative interest coverage ratio of -0.2x indicates inability to cover debt service from operating income
- Long-term debt of $21.8M exceeds cash position of $25.9M, creating leverage risk
- Diluted EPS is negative at -$0.23, reflecting shareholder value destruction
- Operating losses persist despite significant revenue growth, suggesting operational inefficiencies
- Net income remains negative at -$4.60M, showing the company has not yet achieved durable bottom-line profitability
- Interest coverage of -0.2x indicates current operating earnings do not adequately cover financing costs
- Debt/equity of 0.83x and relatively modest equity base increase balance sheet sensitivity if growth slows
Key Metrics to Watch
- Path to operating profitability and timeline to positive net income
- Operating cash flow sustainability as revenue scales
- Debt reduction progress and leverage ratio trends
- Gross margin stability as product mix and manufacturing scale evolve
- Cash burn rate relative to cash reserves and runway
- Operating margin progression toward sustained positive EBIT
- Free cash flow durability alongside revenue growth
Eton Pharmaceuticals, Inc. (ETON) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Eton Pharmaceuticals, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ETON Profit Margin, ROE & Profitability Analysis
ETON vs Healthcare Sector: How Eton Pharmaceuticals, Inc. Compares
How Eton Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Eton Pharmaceuticals, Inc. Stock Overvalued? ETON Valuation Analysis 2026
Based on fundamental analysis, Eton Pharmaceuticals, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Eton Pharmaceuticals, Inc. Balance Sheet: ETON Debt, Cash & Liquidity
ETON Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Eton Pharmaceuticals, Inc.'s revenue has grown significantly by 266% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.04 indicates the company is currently unprofitable.
ETON Revenue Growth, EPS Growth & YoY Performance
ETON Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.3M | $627.0K | $0.02 |
| Q2 2025 | $9.1M | -$2.6M | N/A |
| Q1 2025 | $8.0M | -$811.0K | N/A |
| Q3 2024 | $7.0M | -$579.0K | $-0.02 |
| Q2 2024 | $9.1M | $1.9M | $0.07 |
| Q1 2024 | $5.3M | -$811.0K | $-0.03 |
| Q3 2023 | $3.2M | -$579.0K | $-0.02 |
| Q2 2023 | $7.4M | -$1.6M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Eton Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ETON SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Eton Pharmaceuticals, Inc. (CIK: 0001710340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ETON
What is the AI rating for ETON?
Eton Pharmaceuticals, Inc. (ETON) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ETON's key strengths?
Claude: Revenue growth of 104.9% YoY demonstrates strong top-line expansion. Healthy gross margin of 53.5% indicates pricing power and favorable product mix. ChatGPT: Revenue growth of 104.9% YoY indicates strong commercial execution and expanding product contribution. Positive operating cash flow of $10.52M and free cash flow of $10.19M show improving earnings quality and cash conversion.
What are the risks of investing in ETON?
Claude: Company is unprofitable with net loss of -$4.6M and operating margin of -1.1%. Negative interest coverage ratio of -0.2x indicates inability to cover debt service from operating income. ChatGPT: Net income remains negative at -$4.60M, showing the company has not yet achieved durable bottom-line profitability. Interest coverage of -0.2x indicates current operating earnings do not adequately cover financing costs.
What is ETON's revenue and growth?
Eton Pharmaceuticals, Inc. reported revenue of $80.0M.
Does ETON pay dividends?
Eton Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ETON SEC filings?
Official SEC filings for Eton Pharmaceuticals, Inc. (CIK: 0001710340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ETON's EPS?
Eton Pharmaceuticals, Inc. has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ETON a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Eton Pharmaceuticals, Inc. has a BUY rating with 67% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ETON stock overvalued or undervalued?
Valuation metrics for ETON: ROE of -17.6% (sector avg: 15%), net margin of -5.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ETON stock in 2026?
Our dual AI analysis gives Eton Pharmaceuticals, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ETON's free cash flow?
Eton Pharmaceuticals, Inc.'s operating cash flow is $10.5M, with capital expenditures of $333.0K. FCF margin is 12.7%.
How does ETON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.8% (avg: 12%), ROE -17.6% (avg: 15%), current ratio 1.57 (avg: 2).